Related Experiment Video
Updated: Sep 13, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Hypertension and kidney dysfunction despite long-term remission of Cushing's syndrome
Katrin Ritzel1, Vanessa Fedtke2, Cornelia Then2
1Department of Medicine IV, Ludwig-Maximilians-Universität München, LMU University Hospital, LMU Munich, Ziemssenstrasse 5, 80336, Munich, Germany. Katrin.Ritzel@med.uni-muenchen.de.
Insights
Hypertension and impaired kidney function persist long-term after Cushing's syndrome (CS) remission. Increased monitoring and treatment of these comorbidities are crucial for better patient outcomes.
Area of Science:
- Endocrinology
- Nephrology
- Cardiology
Background:
- Hypertension is a frequent comorbidity in active Cushing's syndrome (CS), posing significant cardiovascular risks.
- Long-term recovery of blood pressure and kidney function after CS remission remains unclear.
Purpose of the Study:
- To investigate the long-term effects of Cushing's syndrome remission on blood pressure and kidney function.
- To assess the prevalence of hypertension and chronic kidney disease in patients post-CS remission.
Main Methods:
- A cohort of 81 CS patients (various types) were longitudinally evaluated post-biochemical remission at 7.1 and 14 years.
- Blood pressure, kidney function (GFR), and comorbidities were analyzed.
- Data were compared to a matched control group (KORA study).
Main Results:
- CS patients exhibited higher blood pressure and lower GFR than controls at all follow-up points.
- Prevalence of hypertension and chronic kidney disease increased over time in both groups, but remained significantly higher in CS patients.
- Uncontrolled hypertension rates increased in the CS cohort due to declining antihypertensive medication use.
Conclusions:
- Elevated hypertension and impaired kidney function persist years after CS remission.
- These persistent comorbidities may lead to unfavorable long-term clinical outcomes.
- Enhanced monitoring and management of comorbidities are essential for CS patients post-remission.
Purpose:
Hypertension is the most frequent co-morbidity in active Cushing's syndrome (CS) and regarded as a major cardio-vascular risk factor. It is unknown whether blood pressure and related parameters, such as kidney function, recover in the long-term following remission of CS.
Methods:
Blood pressure and related co-morbidities were analyzed in a cohort of 81 patients with CS (Cushing's disease: 52, ectopic CS: 8, adrenal CS: 21) from a single tertiary care center. Patients were longitudinally evaluated at baseline, at 7.1 years (6.3-7.4) and at 14 years (13.5-14.4) after biochemical remission. Data were compared to a control group matched for BMI, age and sex (n = 243) from the "Cooperative Health Research in the Region of Augsburg" study (KORA) in a 1:3 fashion.
Results:
Patients with CS showed a higher median blood pressure and lower median glomerular filtration rate (GFR) compared to the matched controls, at baseline, 7 and 14 years after biochemical remission. Although the prevalence of hypertension and chronic kidney disease increased over time in the KORA cohort, patients treated for CS had a significantly higher prevalence of both comorbidities. Notably, the number of patients on antihypertensive medication declined in the Cushing's cohort, resulting in significantly higher rates of uncontrolled hypertension at follow-up.
Conclusion:
The prevalence of hypertension and impaired kidney function remained elevated in patients with CS years after biochemical remission, potentially contributing to an unfavorable long-term clinical outcome. This highlights the critical need for increased monitoring and treatment of co-morbidities in patients with CS following surgical remission.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Potassium-Sparing Diuretics

